National Institute Of Immunology

The SPAG9 antigen developed by the National Institute of Immunology (NII) has received the ASPAGNIITM trademark, the Department of Biotechnology (DBT) said on Friday.

An immunogenicity study conducted on mice for the coronavirus vaccine candidate being developed by the National Institute of Immunology has shown encouraging results, NII director Amulya Panda said on Friday.

A 2009 clinical trial in Thailand was the first to show it was possible to prevent HIV infection in humans. Now scientists believe a licensed vaccine is within reach.

The SPAG9 antigen developed by the National Institute of Immunology (NII) has received the ASPAGNIITM trademark, the Department of Biotechnology (DBT) said on Friday.

An immunogenicity study conducted on mice for the coronavirus vaccine candidate being developed by the National Institute of Immunology has shown encouraging results, NII director Amulya Panda said on Friday.

A 2009 clinical trial in Thailand was the first to show it was possible to prevent HIV infection in humans. Now scientists believe a licensed vaccine is within reach.